Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix, said, “In this trial, we will be using sophisticated molecular mapping technology to analyze ovarian cancer tissue samples removed from study participants. Such data, complementing that already generated by testing discrete ovarian cancer cell-lines, will anchor our understanding of Kevetrin’s multimodal mechanism of action, providing a more complete understanding of its full potential as a novel cancer treatment.”




http://www.ipharminc.com/press-release/2017/2/10/cellceutix-announces-initiation-of-main-clinical-site-for-phase-2a-trial-of-p53-drug-candidate-kevetrin-in-the-treatment-of-platinum-resistantrefractory-ovarian-cancer